17 research outputs found
Recommended from our members
Turbocharger Lubrication - Lubricant Behavior and Factors That Cause Turbocharger Failure
This paper is a review of the turbocharger lubrication system and at the same time an attempt to point out and analyze the factors responsible for turbocharger wear, damage and failures. In particular, the conditions under which the lubricant works are presented, from its entrance up to its exit from the turbocharger bearing housing. Additionally, the consequences of failure to comply with the instructions for appropriate turbocharger operation are provided by the various manufacturers. Water cooled turbochargers (for which engine coolant is used), contribute significantly to the reduction of lubricant temperature, in the critical zones of its operation. This is achieved by reducing, the danger of the oil “coking” effect (charred oil residues) or its decomposition, because of high temperature occurring in these zones. Turbochargers shaft support development using semi-floating bush bearings has a significant impact on turbocharger manufacturing cost, as well as on their operational features. Further benefit may be had, when ball bearings are used (usually angular contact bearings are used) for turbocharger shaft support as they provide: a) a reduction of the kinetic friction coefficient, b) reduction of turbocharger lag during turbocharger shaft acceleration from low to high speeds, and c) reduced sealing problems. Regarding the failures that occur in turbochargers, their majority - up to 50% - is caused by problematic lubrication [1]. The rest of the failures are divided between causes related to human factors (such as misuse and inadequate maintenance of a turbocharged vehicle) and external factors such as foreign objects entering either the compressor or turbine housings
Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study
Among patients with von Willebrand disease (VWD) who are unresponsive to desmopressin therapy, replacement with plasma-derived concentrates is the treatment of choice. Because prospective studies are lacking, such treatment has been largely empirical. A multicenter, prospective study has been conducted in 81 patients with VWD (15 patients with type 1, 34 with type 2, and 32 with type 3 disease) to investigate the efficacy of a high-purity factor VIII/von Willebrand factor (FVIII/VWF) concentrate for treatment of bleeding and surgical prophylaxis. Two preparations of the concentrate-one virally inactivated with solvent detergent, the other with an additional heat-treatment step--were evaluated. Pharmacokinetic parameters were similar for both preparations. Using pre-established dosages based on the results of pharmacokinetic studies, 53 patients were administered either preparation for the treatment of 87 bleeding episodes, and 39 patients were treated prophylactically for 71 surgical or invasive procedures. Sixty-five (74.7%) and 10 (11.5%) of the bleeding episodes were controlled with 1 or 2 infusions, respectively. Patients with severe type 3 VWD typically required more infusions and higher doses, at shorter time intervals, than did patients with generally milder types 1 and 2. Among patients undergoing surgical procedures, blood loss was lower than that predicted prospectively, and losses exceeding the predicted value did not correlate with the postinfusion skin bleeding time. In conclusion, the concentrate effectively stopped active bleeding and provided adequate hemostasis for surgical or invasive procedures, even in the absence of bleeding time correction